This regulatory clearance represents a crucial advancement in Sensorion’s strategic development of SENS-601, which stands as its lead gene therapy program for GJB2-related hearing loss. The company has demonstrated a clear strategic focus earlier this year by submitting Clinical Trial Applications (CTAs) in both France and Canada, concurrently shifting significant development resources towards the SENS-601 program. This strategic realignment came with a decision to pivot away from SENS-501, its previous gene therapy candidate which targeted OTOF-related hearing loss, underscoring the company’s commitment to prioritizing programs with the highest potential impact and likelihood of success based on evolving scientific and clinical understanding. The progression of SENS-601 into clinical trials highlights a growing optimism within the scientific community regarding the potential of gene therapy to fundamentally alter the treatment landscape for inherited forms of deafness.
Unpacking the HearConnex Phase I/II Trial Design
The HearConnex clinical trial is meticulously designed as a two-part, open-label study, aiming to evaluate the safety, tolerability, and preliminary efficacy of SENS-601 in a critically underserved patient population: children diagnosed with congenital DFNB1A hearing loss associated with GJB2 mutations. This specific patient group is often identified early in life, and the profound impact of their condition necessitates innovative therapeutic approaches.
The initial phase of the trial will focus on assessing the safety and tolerability of SENS-601. This will involve unilateral intra-cochlear administration across two ascending-dose cohorts. This methodical approach is standard for early-phase gene therapy trials, allowing researchers to carefully monitor patient responses to incrementally higher doses, thereby identifying a safe and well-tolerated dosage range before proceeding to broader efficacy evaluations. Unilateral administration, meaning treatment in one ear only, is a common safety precaution in initial gene therapy studies, providing a control in the untreated ear and minimizing potential systemic risks.
Following the successful completion of the safety evaluation, the second portion of the HearConnex trial will transition to evaluating efficacy. This will be conducted within an expansion cohort, utilizing bilateral intra-cochlear administration at the selected optimal dose determined from the initial safety phase. Bilateral administration is crucial for assessing the full therapeutic potential of SENS-601, as GJB2-related hearing loss typically affects both ears. Beyond the primary endpoints of safety and efficacy, researchers will also rigorously assess the performance and usability of Sensorion’s proprietary injection system, a critical component for the precise and safe delivery of the gene therapy directly into the delicate structures of the inner ear. The success of such a highly specialized delivery mechanism is paramount for the overall effectiveness and clinical translation of the therapy.
Leading the French arm of the HearConnex study as Principal Investigator will be Professor Natalie Loundon, M.D., Director of the Center for Research in Pediatric Audiology and a distinguished Pediatric Otolaryngologist and Head and Neck Surgeon at Necker Enfants Malades, AP-HP. Professor Loundon brings invaluable expertise to the trial, emphasizing the complex requirements for such advanced therapeutic interventions. "Children born with GJB2-related hearing loss, and their families, hope for additional therapeutic options that address the underlying cause of the condition," stated Professor Loundon. Her statement highlights the profound unmet medical need and the high stakes associated with this trial. She further elaborated on the necessity of specialized infrastructure: "Bringing gene therapy into the clinic for this population requires a highly specialized surgical and audiological environment, and the teams involved have built this experience over the years notably through the course of our Audiogene clinical trial." This underscores the intricate collaboration required between surgeons, audiologists, geneticists, and researchers to safely and effectively administer such a sophisticated treatment.
Serving as the Coordinating Investigator for the multi-regional HearConnex study will be Dr. Sharon Cushing, a renowned Pediatric Otolaryngologist and Director of the Cochlear Implant Program at The Hospital for Sick Children (SickKids) in Toronto. Dr. Cushing’s leadership will be instrumental in harmonizing clinical protocols and data collection across multiple international sites, ensuring the robustness and generalizability of the trial results. Her extensive experience in pediatric hearing loss and cochlear implantation provides a critical perspective on the current standard of care and the potential transformative impact of gene therapy.
SENS-601: Targeting a Common and Devastating Cause of Genetic Hearing Loss
SENS-601 (GJB2-GT) is an investigational adeno-associated virus (AAV)-based gene therapy, developed through a synergistic collaboration with Professor Christine Petit’s esteemed team at Institut Pasteur—Institut de l’Audition/Institut reConnect. This collaboration brings together Sensorion’s drug development capabilities with world-leading expertise in inner ear biology and genetics, underscoring the scientific rigor underpinning SENS-601.
The therapy is precisely engineered to address hearing loss caused by specific mutations in the GJB2 gene. The GJB2 gene encodes for connexin 26, a protein vital for the formation of gap junctions within the inner ear. These gap junctions are intercellular channels that facilitate the rapid exchange of ions and small molecules between supporting cells in the cochlea, particularly within the organ of Corti. This intricate network is crucial for maintaining the precise ionic balance (endocochlear potential) required for the efficient transduction of sound waves into electrical signals that the brain can interpret. When GJB2 mutations occur, the connexin 26 protein is either absent, dysfunctional, or improperly formed, disrupting this delicate ionic homeostasis. This disruption leads to the degeneration of hair cells and spiral ganglion neurons, resulting in profound sensorineural hearing loss.
Mutations in the GJB2 gene are recognized as one of the most common causes of genetic congenital deafness worldwide. Epidemiological data suggest that GJB2 mutations are estimated to account for approximately 50% of all autosomal recessive non-syndromic hearing loss cases. This makes it a primary genetic target for therapeutic intervention. Despite its high prevalence and significant impact on early childhood development and quality of life, there is currently no approved gene therapy specifically addressing GJB2-related hearing loss. Existing treatments primarily involve assistive devices like hearing aids or cochlear implants, which, while effective in restoring some auditory perception, do not address the underlying genetic cause of the condition. A gene therapy like SENS-601 holds the promise of a disease-modifying treatment, potentially restoring natural hearing function by correcting the genetic defect at its source.
The clinical program for SENS-601 is robustly supported by an extensive body of preclinical studies. These studies, conducted in clinically relevant animal models meticulously developed by Professor Petit’s laboratory, have demonstrated significant hearing restoration following SENS-601 administration. Furthermore, comprehensive toxicology, activity, and manufacturing studies have been completed, meticulously preparing the candidate for human testing. This rigorous preclinical validation is a critical prerequisite for advancing any novel gene therapy into clinical trials, ensuring a strong scientific foundation and an acceptable safety profile.
Fred Chereau, Chief Executive Officer of Sensorion, articulated the profound significance of this regulatory achievement: "Securing approval to initiate HearConnex marks a significant milestone for Sensorion and, above all, for the children and families affected by congenital DFNB1A hearing loss, for whom no treatment addressing the underlying biological cause of the disease exists today." His statement underscores not only the company’s scientific progress but also its deep commitment to addressing a critical unmet medical need and bringing hope to countless families grappling with the challenges of genetic deafness.
A Multi-Regional Regulatory Pathway and Future Outlook
The HearConnex trial is envisioned as a multi-regional clinical trial, reflecting Sensorion’s global ambition to make SENS-601 accessible to patients worldwide. Following the French approval, Sensorion confirmed that Health Canada’s review of its Clinical Trial Application, submitted in June 2026, remains underway. Approval from Canadian authorities would further broaden the scope of the trial and accelerate patient recruitment.
Looking ahead, Sensorion has outlined an aggressive timeline for additional regulatory submissions. The company is targeting the submission of a Clinical Trial Application in Australia and an Investigational New Drug (IND) application in the United States by the end of 2026. Gaining regulatory clearance in these key territories would position SENS-601 as a truly international program, allowing for broader patient access and accelerating the collection of diverse clinical data. The US market, in particular, represents a significant opportunity given its robust regulatory framework and large patient population.
To further engage the scientific and investor communities, Sensorion plans to host an online SENS-601 Program Day on September 22, 2026. This dedicated event is expected to provide an in-depth exploration of SENS-601 and the HearConnex trial. The agenda will cover critical aspects, including the underlying science of GJB2-related hearing loss, a detailed profile of the target patient population, the intricate trial design, and the key clinical endpoints that will be used to assess the therapy’s success. The program will feature presentations from distinguished experts, including Professor Christine Petit, who will likely delve into the foundational science and preclinical data, and Dr. Sharon Cushing, who will offer insights into the clinical execution and patient perspective. Members of Sensorion’s management team will also provide updates on the company’s strategic vision and development plans.
Broader Implications for Genetic Hearing Loss Treatment
The initiation of the HearConnex trial for SENS-601 represents a paradigm shift in the approach to treating genetic hearing loss. For decades, interventions have primarily focused on symptomatic management rather than addressing the root cause. Gene therapy offers the potential to fundamentally alter the disease course, potentially restoring natural auditory function and significantly improving developmental outcomes for affected children. This milestone not only validates Sensorion’s innovative research and development efforts but also strengthens the broader field of otologic gene therapy, demonstrating the feasibility of delivering genetic material to the delicate and complex structures of the inner ear.
The successful progression of SENS-601 could also pave the way for other gene therapy candidates targeting different forms of inherited hearing loss. The expertise gained in vector design, delivery mechanisms, surgical techniques for intra-cochlear administration, and patient monitoring will be invaluable for future programs. However, challenges remain significant, including ensuring long-term safety and durability of effect, scaling manufacturing processes, and navigating complex regulatory landscapes across different regions.
For the patient community, this news instills renewed hope. GJB2-related hearing loss profoundly impacts communication, education, and social development from an early age. A successful gene therapy could offer children the opportunity to develop listening and spoken language skills in a more natural way, reducing the reliance on external devices and mitigating some of the lifelong challenges associated with profound hearing impairment. The collaborative nature of the trial, involving leading pediatric audiology and otolaryngology centers, underscores the commitment of the medical community to explore all avenues for improving the lives of these children. The journey from preclinical research to an approved therapy is long and arduous, but Sensorion’s HearConnex trial is a beacon of progress, marking a critical step towards a future where genetic hearing loss can be effectively treated at its source.
Source: Sensorion
